Wells Fargo raises Regeneron stock price target to $925 on execution
Covered in this story
What has happened since
- Regeneron Pharmaceuticals is down 0.6% since this was published, 12 days ago.
- Wells Fargo is up 0.2% since this was published, 12 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Wells Fargo’s $925 target on $REGN is on the record and being tracked to Nov 2027 (12-month default), scored on the close that day.
Wells Fargo’s track record →Analyst targets on Regeneron Pharmaceuticals
- Raymond James: at $819 · target $1.02k by Oct 2027 · Outperform via Investing.com
- Jefferies: at $735 · target $930 by Oct 2027 · Buy via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $REGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Regeneron Pharmaceuticals →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.